News For CELG From The Last 14 Days Check below for free stories on CELG the last two weeks.
There are 7 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
January 31, 2010
|
| 22:07 EDT |  | CELG |
| theflyonthewall.com: | Barron's says many financially strong companies that don't pay dividends should |
 Subscribe for More Information :theflyonthewall.com |
|
|
January 28, 2010
|
| 13:52 EDT |  | CELG |
| theflyonthewall.com: | Celgene shares defended at Citigroup | | :theflyonthewall.com |
| | 07:32 EDT |  | CELG |
| | 07:31 EDT | | CELG |
|
|
January 27, 2010
|
| 16:43 EDT |  | CELG |
| theflyonthewall.com: | On The Fly: U.S. Market Wrap-Up for Wednesday 1/27 | | The markets opened slightly lower but quickly advanced into positive territory. The move, however, was short-lived. After a disappointing new home sales report brought out the sellers, the markets drifted lower. Once they crossed back into negative territory, the selling accelerated until each of the major indices was lower by at least 0.50%. The averages sat in a narrow range until the release of the FOMC rate decision. The knee jerk reaction was to sell on the news, but the averages quickly reversed and pushed into positive territory by the close…The Dow rose 41.87 to 10,236.16, the S&P gained 5.33 to 1,097.50, and the Nasdaq added 17.68 to 2,221.41…Among the biggest gainers: Sanmina-SCI Corp. (SANM) surged 15% to $14.15 after beating Q1 EPS estimates by a wide margin. Super Micro Computer (SMCI) soared 16.3% to $13.50 after forecasting better-than-expected Q3 EPS estimates…The losers included: Caterpillar (CAT) which slumped 4.3% to $53.44 after reporting Q4 earnings that fell 65%. The company also issued a disappointing FY10 forecast. Jackson Hewitt (JTX) dropped 16.5% to 2.94 after reporting that it does not believe it can finance its refund anticipation loans…CURRENCY: The dollar closed 0.36% higher on the yen at 89.93 and 0.41% lower on the euro at 0.7132…COMMODITIES: Crude oil closed down 1.05 to 73.66...Natural gas lost 0.19 to 5.24...Gold was lower by 13.00 to 1,086.50…ECONOMIC DATA: New Home Sales for December fell 7.6% to an annual sales rate of 342K versus a consensus range of 350K to 385K. MBA Purchase Applications for the week of 1/22 fell 3.3%. Crude Inventories for the week of January 22 were down -3.88M vs. consensus of 1.5M build. Gasoline inventories 1.99M vs. consensus of 900K build. Distillates 358K vs. consensus of 1.8M draw. The FOMC left interest rates unchanged between 0%-0.25% and expects rates to remain low for “an extended period.” They also said that MBS purchases will end in March as scheduled. Tomorrow…Durable Goods Orders, Jobless Claims, and EIA Natural Gas Report are due…Notable companies reporting Thursday before the opening bell include: Altria Group (MO), AT&T (T), Ball Corporation (BLL), Becton Dickinson and Company (BDX), Bemis (BMS), Bristol-Myers Squibb (BMY), Cardinal Health (CAH), Celgene (CELG), Consol Energy (CNX), Dominion Resources (D), Eastman Kodak (EK), EQT Corporation (EQT), Ford (F), Franklin Resources (BEN), Goodrich (GR), Invesco (IVZ), Janus Capital (JNS), L-3 Communications (LLL), Life Technologies (LIFE), Lockheed Martin (LMT), Motorola (MOT), Raytheon (RTN), Rockwell Collins (ROK), Textron (TXT), The Estee Lauder Companies (EL), Timer Warner Cable (TWC), Xcel Energy (XEL), and Zimmer Holdings (ZMH). :theflyonthewall.com |
| | 15:32 EDT | | CELG |
| | 13:34 EDT | | CELG |
| theflyonthewall.com: | Earnings Preview: Celgene could beat and raise on Revlimid sales | | Celgene Corp. (CELG) is expected to report Q4 earnings before the market open on Thursday, January 28, with a conference call scheduled for 9 am ET. The consensus estimate is 62c for EPS and $743.32M for revenue, according to First Call. On January 11, Celgene pre-announced its Q4 results with an EPS view of 62c. Positive drivers for the company include expanding usage and international growth of Revlimid and the company's healthy pipeline. Possible negative drivers for Celgene include an overestimation of Revlimid sales and the increasingly competitive blood cancer market. On January 13, Celgene's target was raised to $68 from $60 at RBC Capital, reflecting what the firm sees as new positive data on Revlimid and bullish 2010 revenue guidance, as well as better than expected Q4 results. The firm maintains an Outperform rating on the stock. :theflyonthewall.com |
|
|
|
